Who makes Nitisinone in Arm A?

Nitisinone in Arm A is developed by Swedish Orphan Biovitrum.

What development phase is Nitisinone in Arm A in?

Nitisinone in Arm A is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Nitisinone in Arm A

Swedish Orphan Biovitrum · Phase 1 active Small molecule

At a glance

Generic name	Nitisinone in Arm A
Also known as	Orfadin
Sponsor	Swedish Orphan Biovitrum
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nitisinone in Arm A CI brief — competitive landscape report
Nitisinone in Arm A updates RSS · CI watch RSS
Swedish Orphan Biovitrum portfolio CI